ICER VP Discusses Adding the Patient Voice to Value Assessments

Vice President of Patient Engagement at the Institute for Clinical and Economic Review (ICER) Yvette Venable highlights the importance of considering the patient perspective when evaluating a drug’s value. Her role was established in response to a growing recognition that the patient voice can be distinct from quantitative assessments of novel therapies.

Venable “[D]iscusses how ICER has engaged with patient organizations and incorporated the patient voice in its drug value assessments, and the importance of this.” Read more here.

(Source: Yvette Venable, The Evidence Base, 7/13/21)